Loading
BTG1 (BTG anti-proliferation factor 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Diffuse large B-cell lymphoma and 1 more.
Anti-proliferative protein.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.65 (direct and indirect evidence; datatypes literature 0.96, animal model 0.47, genetic association 0.28, somatic mutation 0.79). IntOGen calls it a driver in 6 cohorts (3 activating, 3 loss-of-function), covering Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, NOS, Non-Hodgkin Lymphoma, Plasma Cell Myeloma.
In plain words · BTG1 (BTG anti-proliferation factor 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Diffuse large B-cell lymphoma and 1 more.
BTG1 (BTG anti-proliferation factor 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Diffuse large B-cell lymphoma and 1 more.
Anti-proliferative protein. Locus 12q21.33 (HGNC).
No product in this corpus aims at BTG1 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance) and a fusion partner (UniProt records a translocation), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA BTG1: RNA tissue enhanced (bone marrow 89 nTPM); no normal tissue stained high. Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lymphoma, Multiple myeloma, Leukaemia); Open Targets associates it with 1 specific cancer type at or above 0.5 (diffuse large B-cell lymphoma). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P62324; CIViC gene BTG1; IntOGen BTG1; Human Protein Atlas BTG1 tissue; Open Targets ENSG00000133639 associations
First described 1992. Earliest sequence paper UniProt cites for the protein: Rouault J.-P. et al, EMBO J, 1992, "BTG1, a member of a new family of antiproliferative genes". Source.
Sources: HGNC HGNC:1130 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P62324 (protein name, function text, keywords and locations (REST API)); CIViC gene BTG1 (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000133639 (association with cancer (MONDO_0004992) 0.65; per-cancer scores at or above 0.5: diffuse large B-cell lymphoma 0.63, non-Hodgkin lymphoma 0.67 (GraphQL API, CC0)); IntOGen BTG1 (driver in 6 cohorts (Act 3, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Anti-proliferative protein. Locus 12q21.33 (HGNC).
RNA: tissue enhanced (bone marrow 89 nTPM), detected in all normal tissues.
No normal tissue stained high.
No cancer sample stained medium or high.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"BTG1" OR ABSTRACT:"BTG1" OR TITLE:"BTG anti-proliferation factor 1" OR ABSTRACT:"BTG anti-proliferation factor 1" OR TITLE:"APRO2" OR ABSTRACT:"APRO2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BTG1, not a curated reading list.